Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tvardi Therapeutics (TVRD) Other Non-Current Liabilities (2023 - 2025)

Tvardi Therapeutics' Other Non-Current Liabilities history spans 3 years, with the latest figure at $45.8 million for Q1 2025.

  • On a quarterly basis, Other Non-Current Liabilities rose 19.4% to $45.8 million in Q1 2025 year-over-year; TTM through Mar 2025 was $45.8 million, a 19.4% increase, with the full-year FY2024 number at $44.4 million, up 19.87% from a year prior.
  • Other Non-Current Liabilities hit $45.8 million in Q1 2025 for Tvardi Therapeutics, up from $44.4 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for TVRD hit a ceiling of $45.8 million in Q1 2025 and a floor of $37.1 million in Q4 2023.
  • Historically, Other Non-Current Liabilities has averaged $41.0 million across 3 years, with a median of $40.1 million in 2024.
  • Biggest five-year swings in Other Non-Current Liabilities: increased 19.87% in 2024 and later grew 19.4% in 2025.
  • Tracing TVRD's Other Non-Current Liabilities over 3 years: stood at $37.1 million in 2023, then increased by 19.87% to $44.4 million in 2024, then grew by 3.09% to $45.8 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for TVRD at $45.8 million in Q1 2025, $44.4 million in Q4 2024, and $40.6 million in Q3 2024.